News headlines about Flex Pharma (NASDAQ:FLKS) have been trending somewhat positive on Tuesday, according to Accern Sentiment. Accern rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Flex Pharma earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.75172695394 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the media stories that may have impacted Accern’s analysis:
- Contrasting Flex Pharma (FLKS) & Its Rivals (americanbankingnews.com)
- Flex Pharma (FLKS) Rating Increased to Buy at Zacks Investment Research (americanbankingnews.com)
- Analysts Expect Flex Pharma, Inc. (FLKS) Will Post Quarterly Sales of $380,000.00 (americanbankingnews.com)
- Flex Pharma : Enrollment Completed in Flex Pharma’s Phase 2 Exploratory Spasticity Study in MS (4-traders.com)
Shares of Flex Pharma (NASDAQ:FLKS) traded up $0.13 during trading hours on Tuesday, reaching $4.31. The company had a trading volume of 12,300 shares, compared to its average volume of 74,644. Flex Pharma has a 12 month low of $2.68 and a 12 month high of $6.49.
Several research analysts recently issued reports on FLKS shares. Zacks Investment Research lowered Flex Pharma from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $10.00 target price on shares of Flex Pharma in a research report on Monday, September 25th. Finally, Roth Capital started coverage on Flex Pharma in a research report on Thursday, September 7th. They set a “buy” rating and a $14.00 target price on the stock. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $9.75.
WARNING: This news story was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.com-unik.info/2017/12/05/flex-pharma-flks-earns-news-impact-rating-of-0-20.html.
About Flex Pharma
Flex Pharma, Inc is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.
What are top analysts saying about Flex Pharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Flex Pharma Inc. and related companies.